RetaCalc
Protocol library
SingleInvestigationalPhase 2Moderate confidenceSourced

Cagrilintide

A long-acting amylin analogue under clinical investigation for weight management, with dose-ranging human evidence but no routine-use authorisation.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Phase 2 dose-finding study

Weekly research quantities

The line reproduces the five cagrilintide arms and their two-week escalation intervals from the registered 26-week phase 2 study.

Evidence source
Maximum study quantityChoose the maximum shown by the evidence line. Any earlier point can be selected below for its arithmetic.

Assigned weekly quantities

Select a point for its calculation examples
  1. Weeks 1 to 2
    0.6 mg
  2. Weeks 3 to 4
    1.2 mg
    +0.6 mg after 2 weeks
  3. Weeks 5 to 6
    2.4 mg
    +1.2 mg after 2 weeks
  4. Weeks 7 to 26
    4.5 mg
    +2.1 mg after 2 weeks

Vial-aware arithmetic

Reconstitution examples, up to 3 mL

Choose the vial quantity and BAC water first. The diagram and results below update for the selected 0.6 mg study quantity. Higher-strength vials may naturally land outside the 20-30 unit band.

Vial quantity

Choose the quantity printed on the vial.

BAC water added

Use 1, 2 or 3 mL, or enter a custom volume up to 3 mL.

Open the full reverse calculator
Three millilitre research vial, diluent vial and capped U-100 syringe on an ink-blue surface
One small vial, one measured diluent volume and one U-100 scale. The arithmetic connects all three.
BAC water selected
3 mL

Basic example limit: 3 mL maximum. Check the actual vial and product-specific limits.

1 mL BAC
6 units

resulting U-100 draw

Concentration
10 mg/mL
BAC added
1 mL
2 mL BAC
12 units

resulting U-100 draw

Concentration
5 mg/mL
BAC added
2 mL
3 mL BAC
18 units

resulting U-100 draw

Concentration
3.333 mg/mL
BAC added
3 mL

Shown in the diagram. Closest of these examples to 25 units.

Formula: draw units = selected mg × BAC mL ÷ vial mg × 100. The 20-30 unit band is a measurement reference, not a recommendation. Results are mathematical examples, not preparation instructions.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Human StudySubcutaneousOnce weekly
Adults with overweight or obesity without diabetes

Once-weekly dose-finding arms of 0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg and 4.5 mg with escalation every 2 weeks

Phase 2 research allocation over 26 weeks with placebo and liraglutide comparators.

View source
Community GuideSubcutaneous in reportsOnce weekly
online research community stacking reports

Low-dose stacking reports cluster around 0.125-0.25 mg subcutaneously once weekly, with most surveyed users below 0.5 mg weekly

These are community experiments, not trial arms. The same channel reports responses ranging from 70-80 mcg being strong to 1.2 mg or more producing little effect, alongside fatigue and mood complaints; raw/incretin-mimetics/im-cagrilintide.md:3041-3160.

View source

Evidence summary

The phase 2 dose-finding study evaluated several assigned doses and an active comparator. It was designed to characterise efficacy, tolerability and dose response under research monitoring.

Interpretation

Trial arms should not be converted into self-directed schedules. Ongoing development may change the selected formulation, regimen and regulatory conclusions.

Warnings and contraindications

Cagrilintide remains investigational and trial regimens are not prescribing guidance.
Gastrointestinal adverse events were common in the phase 2 study.
Organised research bench with labelled storage tray, vial rack, notebook and thermometer
A clean workspace supports traceability. It does not establish sterility.

Shared across protocols

Supplies and general handling

Keep the universal checklist short. Product-specific labelling and source documentation always take priority over a general guide.

Research vial

Select the labelled vial quantity used in the calculation.

View Peppys vial

Bacteriostatic water

Use only a diluent appropriate to the research method and formulation.

View Peppys BAC water

U-100 measuring syringe

Use a new sterile device for every entry. Source locally.

Source locally

Wipes and sharps container

Plan clean handling and immediate sharps disposal. Source locally.

Source locally

Storage follows the label

Do not apply a universal refrigerator rule. Follow the product, diluent and study documentation for temperature, light and expiry.

Use sterile equipment once

CDC injection-safety guidance calls for a new sterile needle and syringe for each injection and entry into a medication container.

Stability is formulation-specific

Do not infer a post-mixing lifetime from BAC water alone. Discard material when identity, integrity or sterility is in doubt.

General references: CDC injection safety, NHS medicine storage and DailyMed BAC water labelling.